Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis

Maurizio Battaglia Parodi, Pierluigi Iacono, Dimitrios Stelyos Kontadakis, Ilaria Zucchiatti, Maria Lucia Cascavilla, Francesco Bandello

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: To compare the effectiveness of photodynamic therapy (PDT) vs intravitreal bevacizumab injection in patients with subfoveal choroidal neovascularization (CNV) secondary to multifocal choroiditis (MC). Methods: Patients affected by subfoveal CNV associated with MC referred for clinical evaluation from March 1, 2005, to July 31, 2008, were considered for this pilot randomized clinical trial. Twenty-seven patients were included in the study and followed up from March 15, 2005, through April 30, 2009. After randomization, patients receiving PDT were treated according to the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy protocol, whereas patients receiving intravitreal bevacizumab injection, after a loading phase of 3 monthly injections, were examined monthly and re-treated on the basis of detection of fluid on optical coherence tomography and/or leakage on fluorescein angiography. Main Outcome Measures: The primary outcome measure was the 5- and 15-letter change on the Early Treatment of Diabetic Retinopathy Study charts at 12-month examinations compared with baseline. Secondary outcomes included central macular thickness changes. Results: Thirteen and 14 patients were randomized to PDT and bevacizumab treatment, respectively. At the 12-month examination, 5 of 14 eyes treated with bevacizumab and 0 of 13 eyes treated with PDT experienced a best-corrected visual acuity gain of greater than 3 lines (P=.04). Twelve eyes in the bevacizumab group and 6 eyes in the PDT group gained more than 1 line (P=.04). The central macular thickness showed a progressive reduction in both subgroups without a significant difference compared with the baseline values. Conclusions: Greater beneficial effects can be achieved using intravitreal bevacizumab injection rather than PDT for the treatment of subfoveal CNV secondary to MC. Larger multicenter investigations are needed to confirm our preliminary results. Application to Clinical Practice: Currently, there is no precise indication regarding the best therapeutic approach to subfoveal CNV secondary to MC. This investigation was designed to verify whether intravitreal bevacizumab injection has a more beneficial effect with respect to PDT.

Original languageEnglish
Pages (from-to)1100-1103
Number of pages4
JournalArchives of Ophthalmology
Volume128
Issue number9
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Choroidal Neovascularization
Photochemotherapy
Intravitreal Injections
Outcome Assessment (Health Care)
Therapeutics
Multifocal choroiditis
Bevacizumab
Fluorescein Angiography
Optical Coherence Tomography
Macular Degeneration
Diabetic Retinopathy
Random Allocation
Visual Acuity
Randomized Controlled Trials
Injections

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis. / Parodi, Maurizio Battaglia; Iacono, Pierluigi; Kontadakis, Dimitrios Stelyos; Zucchiatti, Ilaria; Cascavilla, Maria Lucia; Bandello, Francesco.

In: Archives of Ophthalmology, Vol. 128, No. 9, 09.2010, p. 1100-1103.

Research output: Contribution to journalArticle

Parodi, Maurizio Battaglia ; Iacono, Pierluigi ; Kontadakis, Dimitrios Stelyos ; Zucchiatti, Ilaria ; Cascavilla, Maria Lucia ; Bandello, Francesco. / Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis. In: Archives of Ophthalmology. 2010 ; Vol. 128, No. 9. pp. 1100-1103.
@article{cfcd043747da47bab43c6608ff374f44,
title = "Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis",
abstract = "Objective: To compare the effectiveness of photodynamic therapy (PDT) vs intravitreal bevacizumab injection in patients with subfoveal choroidal neovascularization (CNV) secondary to multifocal choroiditis (MC). Methods: Patients affected by subfoveal CNV associated with MC referred for clinical evaluation from March 1, 2005, to July 31, 2008, were considered for this pilot randomized clinical trial. Twenty-seven patients were included in the study and followed up from March 15, 2005, through April 30, 2009. After randomization, patients receiving PDT were treated according to the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy protocol, whereas patients receiving intravitreal bevacizumab injection, after a loading phase of 3 monthly injections, were examined monthly and re-treated on the basis of detection of fluid on optical coherence tomography and/or leakage on fluorescein angiography. Main Outcome Measures: The primary outcome measure was the 5- and 15-letter change on the Early Treatment of Diabetic Retinopathy Study charts at 12-month examinations compared with baseline. Secondary outcomes included central macular thickness changes. Results: Thirteen and 14 patients were randomized to PDT and bevacizumab treatment, respectively. At the 12-month examination, 5 of 14 eyes treated with bevacizumab and 0 of 13 eyes treated with PDT experienced a best-corrected visual acuity gain of greater than 3 lines (P=.04). Twelve eyes in the bevacizumab group and 6 eyes in the PDT group gained more than 1 line (P=.04). The central macular thickness showed a progressive reduction in both subgroups without a significant difference compared with the baseline values. Conclusions: Greater beneficial effects can be achieved using intravitreal bevacizumab injection rather than PDT for the treatment of subfoveal CNV secondary to MC. Larger multicenter investigations are needed to confirm our preliminary results. Application to Clinical Practice: Currently, there is no precise indication regarding the best therapeutic approach to subfoveal CNV secondary to MC. This investigation was designed to verify whether intravitreal bevacizumab injection has a more beneficial effect with respect to PDT.",
author = "Parodi, {Maurizio Battaglia} and Pierluigi Iacono and Kontadakis, {Dimitrios Stelyos} and Ilaria Zucchiatti and Cascavilla, {Maria Lucia} and Francesco Bandello",
year = "2010",
month = "9",
doi = "10.1001/archophthalmol.2010.205",
language = "English",
volume = "128",
pages = "1100--1103",
journal = "Archives of Ophthalmology",
issn = "0003-9950",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis

AU - Parodi, Maurizio Battaglia

AU - Iacono, Pierluigi

AU - Kontadakis, Dimitrios Stelyos

AU - Zucchiatti, Ilaria

AU - Cascavilla, Maria Lucia

AU - Bandello, Francesco

PY - 2010/9

Y1 - 2010/9

N2 - Objective: To compare the effectiveness of photodynamic therapy (PDT) vs intravitreal bevacizumab injection in patients with subfoveal choroidal neovascularization (CNV) secondary to multifocal choroiditis (MC). Methods: Patients affected by subfoveal CNV associated with MC referred for clinical evaluation from March 1, 2005, to July 31, 2008, were considered for this pilot randomized clinical trial. Twenty-seven patients were included in the study and followed up from March 15, 2005, through April 30, 2009. After randomization, patients receiving PDT were treated according to the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy protocol, whereas patients receiving intravitreal bevacizumab injection, after a loading phase of 3 monthly injections, were examined monthly and re-treated on the basis of detection of fluid on optical coherence tomography and/or leakage on fluorescein angiography. Main Outcome Measures: The primary outcome measure was the 5- and 15-letter change on the Early Treatment of Diabetic Retinopathy Study charts at 12-month examinations compared with baseline. Secondary outcomes included central macular thickness changes. Results: Thirteen and 14 patients were randomized to PDT and bevacizumab treatment, respectively. At the 12-month examination, 5 of 14 eyes treated with bevacizumab and 0 of 13 eyes treated with PDT experienced a best-corrected visual acuity gain of greater than 3 lines (P=.04). Twelve eyes in the bevacizumab group and 6 eyes in the PDT group gained more than 1 line (P=.04). The central macular thickness showed a progressive reduction in both subgroups without a significant difference compared with the baseline values. Conclusions: Greater beneficial effects can be achieved using intravitreal bevacizumab injection rather than PDT for the treatment of subfoveal CNV secondary to MC. Larger multicenter investigations are needed to confirm our preliminary results. Application to Clinical Practice: Currently, there is no precise indication regarding the best therapeutic approach to subfoveal CNV secondary to MC. This investigation was designed to verify whether intravitreal bevacizumab injection has a more beneficial effect with respect to PDT.

AB - Objective: To compare the effectiveness of photodynamic therapy (PDT) vs intravitreal bevacizumab injection in patients with subfoveal choroidal neovascularization (CNV) secondary to multifocal choroiditis (MC). Methods: Patients affected by subfoveal CNV associated with MC referred for clinical evaluation from March 1, 2005, to July 31, 2008, were considered for this pilot randomized clinical trial. Twenty-seven patients were included in the study and followed up from March 15, 2005, through April 30, 2009. After randomization, patients receiving PDT were treated according to the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy protocol, whereas patients receiving intravitreal bevacizumab injection, after a loading phase of 3 monthly injections, were examined monthly and re-treated on the basis of detection of fluid on optical coherence tomography and/or leakage on fluorescein angiography. Main Outcome Measures: The primary outcome measure was the 5- and 15-letter change on the Early Treatment of Diabetic Retinopathy Study charts at 12-month examinations compared with baseline. Secondary outcomes included central macular thickness changes. Results: Thirteen and 14 patients were randomized to PDT and bevacizumab treatment, respectively. At the 12-month examination, 5 of 14 eyes treated with bevacizumab and 0 of 13 eyes treated with PDT experienced a best-corrected visual acuity gain of greater than 3 lines (P=.04). Twelve eyes in the bevacizumab group and 6 eyes in the PDT group gained more than 1 line (P=.04). The central macular thickness showed a progressive reduction in both subgroups without a significant difference compared with the baseline values. Conclusions: Greater beneficial effects can be achieved using intravitreal bevacizumab injection rather than PDT for the treatment of subfoveal CNV secondary to MC. Larger multicenter investigations are needed to confirm our preliminary results. Application to Clinical Practice: Currently, there is no precise indication regarding the best therapeutic approach to subfoveal CNV secondary to MC. This investigation was designed to verify whether intravitreal bevacizumab injection has a more beneficial effect with respect to PDT.

UR - http://www.scopus.com/inward/record.url?scp=77956994431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956994431&partnerID=8YFLogxK

U2 - 10.1001/archophthalmol.2010.205

DO - 10.1001/archophthalmol.2010.205

M3 - Article

VL - 128

SP - 1100

EP - 1103

JO - Archives of Ophthalmology

JF - Archives of Ophthalmology

SN - 0003-9950

IS - 9

ER -